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Abstract.  Monoclonal antibodies that recognize an 
epitope within the triple helix of type HI collagen have 
been used to examine the distribution  of that collagen 
type in human  skin,  cornea,  amnion,  aorta,  and ten- 
don.  Ultrastructural  examination  of those tissues indi- 
cates antibody binding to collagen fibrils in skin,  am- 
nion,  aorta,  and tendon  regardless  of the diameter of 
the fibril.  The antibody distribution  is unchanged  with 
donor age,  site of biopsy, or region of tissue exam- 
ined.  In contrast,  antibody applied to adult human 
cornea localizes to isolated fibrils,  which appear ran- 
domly throughout the matrix.  These studies indicate 
that type m  collagen remains  associated with collagen 
fibrils after removal of the amino and carboxyl 
propeptides,  and  suggests that  fibrils of skin,  tendon, 
and amnion  (and presumably many other tissues that 
contain both types I and m  collagens)  are copolymers 
of at least types I  and III collagens. 
T 
HE morphology of connective tissues is largely deter- 
mined by the size and orientation of collagen fibrils. 
Fibril diameters vary with the tissue studied and the 
developmental stage of that tissue. These observations sug- 
gest that the fibril-forming process is a well controlled series 
of events.  A  number of regulatory mechanisms  have been 
suggested.  These  include  direct  participation  by  cells  in 
fibrillogenesis (Birk and Trelstad,  1986)  as well as the in- 
volvement of posttranslational proteolytic processing of type 
I and III procollagens (Miyahara et al.,  1984; Fleischmajer 
et al., 1985) and possibly type V collagen (Fitch et al., 1984) 
in the control of this process. The latter postulates are sup- 
ported by the observations that types I, III, and V collagens 
share common structural features (Miller, 1985), and that all 
can form fibrils in vitro with the same periodic D-banding 
seen in vivo (Adachi and Hayashi,  1985). 
Types I, III, and V collagens all are present in haman skin 
at all ages but the interrelationships  of these molecules are 
unknown.  In vitro studies of fibrillogenesis have indicated 
the importance of helix-helix interactions in the regulation 
of this process (Birk and Silver,  1984).  Initial studies of in 
vitro fibrillogenesis of mixtures of the triple-helical domains 
from types I  and III collagens  indicated that the resultant 
fibril diameter was inversely proportional to the I/III molar 
ratio (Lapiere et al.,  1977). There is growing evidence that 
the pN- and pC-forms of both types I and HI collagens are 
involved in fibrillogenesis, pN-type I and pN-type III colla- 
gens are present on fibrils of small diameter, but absent from 
fibrils of larger  diameter (Fleischmajer  et al.,  1981, 1983, 
1985;  Sato  et al.,  1986).  The  reported  persistence  of the 
amino propeptide of pN-type I collagen in the thin and hiero- 
glyphic fibrils of dermatosparactic animals (Lenaers et al., 
1971; Becker et al., 1976) suggests that these globular regions 
further deter fiber growth or stabilization. The further obser- 
vation that the amino propeptide of pN-type m  collagen is 
excised far more slowly than the equivalent peptide of pN- 
type I collagen under physiological growth conditions (Fess- 
ler and Fessler,  1979; Fessler et al.,  1981) suggests that the 
limitation to fiber growth may be at least partially related to 
the proteolytic excision of the type III amino propeptide. In 
vitro fiber formation observed during pN-type I to type I col- 
lagen conversion demonstrated a dependence of the rate of 
fibril  formation  upon  the  rate  of removal  of the  amino- 
terminal peptide, but the final fibril diameter was unaffected. 
In similar experiments using pC-type I collagen, the fibril 
formed  concurrent  with  removal of the  carboxyl-terminal 
peptide were of very large diameter (Miyahara et al.,  1984). 
These  observations  suggest  that  the  amino  and  carboxyl 
propeptides of both types I and III collagens may be directly 
involved in regulating fibril growth. The subsequent fate arid 
function of both the excised propeptides and the type III col- 
lagen molecule are unclear. Existing evidence suggests that 
the type III collagen triple helix is absent from the surface 
of large diameter fibrils (Nowack et al.,  1976; Fleischmajer 
et al., 1980). The reported absence of type HI collagen from 
the surface of mature fibers suggests that another mechanism 
may exist that limits the ultimate size of the fibrils, since type 
III collagen, which was observed on fibrils of small diameter, 
must have either been removed or buried within the interior 
of the fibril. 
The present study uses a monoclonal antibody to a defined 
epitope within the triple-helical  domain of human type III 
collagen to investigate the location of type III collagen in hu- 
man dermis, tendon, amnion, aorta, and cornea. The results 
indicate that in skin, tendon, aorta, and amnion, type III col- 
lagen is present on all banded collagen fibrils regardless of 
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donor.  In contrast,  cornea contains only occasional  fibrils 
that contain type III collagen.  These observations  suggest 
that the collagen fibers in type III collagen-containing tissues 
can be copolymers of at least types I and III. 
Materials and Methods 
Monoclonal Antibody Production 
B10.A(4R) mice (Jackson Laboratories, Bar Harbor, ME) were immunized 
with 100 I~g of human type III collagen emulsified in complete Freund's ad- 
juvant. 2 wk later mice were boosted on three consecutive days with 200 
txg of human type III collagen (prepared from human amnion by limited 
pepsin solubilization as described [Burgeson et al., 1976]), and spleen cells 
were fused with the myeloma cell line P3-NSI/I-Ag4-1  (Kohler et al., 1976) 
the fourth day, according to previously described methods (Hollister et al., 
1982; Sakai et al., 1982). Hybridomas were screened for the production of 
antibody by ELISA and by indirect immunofluorescence, and selected colo- 
nies were cloned by limiting dilution. 
Antibody was collected from selected hybridoma clones either in the 
form of spent tissue  culture  medium  or  as ascites  from  B10.A(4R)  x 
BALB/c hybrid mice, pristane-primed, and injected with at least 107 hy- 
bridoma cells. 
Electron Microscopy 
En bloc immunolabeling of tissues by secondary gold conjugates (Sakai  et 
al.,  1986a),  and by the visualization of "naked" IgM primary antibodies 
(Keene et al., 1987) has been previously described. Briefly, human neonatal 
foreskin, autopsy samples including aorta, skin, and cornea obtained within 
24 h after death, and term amnion obtained within 30 min after birth were 
sliced into 0.5-l-ram thick strips. Unfixed tissues were washed in PBS, in- 
cuhated overnight in murine monoclonal anti-human type III collagen IgM 
(mAb-III)  ~ diluted  1:5 in PBS, then extensively washed in PBS. Samples 
were then rinsed in sodium cacodylate buffer, fixed in buffered Karnovsky's 
fixative, pH 7.4 (Karnovsky,  1965), and postfixed in buffered OsO4.  Sam- 
ples were dehydrated in a  graded series of ethanol dilutions, washed in 
propylene oxide, and embedded in Spurr's epoxy. Grids supporting 70-80- 
nm thick sections were stained in 2% uranyl acetate in 50% ethanol for 15 
min followed by Reynold's lead citrate (Reynolds, 1963) for 60 s. Control 
samples were treated in the same manner except that the first antibody was 
omitted, or human IgM and other antibodies of irrelevant specificity were 
substituted for mAb-IIl. "Naked" IgM visualization by transmission elec- 
tron microscopy (TEM) immediately followed. Cornea samples were in- 
cuhated in mAb-III and washed in PBS, and additionally incubated in 5-nm 
colloidal gold conjugated goat  anti-mouse IgM  (Janssen Life Sciences 
Products, Piscataway,  NJ) diluted  1:3 in BSA buffer,  pH 8.2 overnight at 
4~  rinsed in PBS, cacodylate buffer, and fixed, dehydrated, and embedded 
as above. Tendon samples were prepared for TEM by swelling the fibers 
in 0.2 M acetic acid overnight at 4~  after which they were rinsed in PBS, 
pH 7.4 for 15 min, then incubated in mAb-IIl overnight at 4~  as above. 
After an extensive PBS wash, they were either fixed as above and examined 
without secondary conjugate,  or  incubated in 5-nm colloidal gold con- 
jugated anti-IgM. 
Skin samples prepared for scanning electron microscopy (SEM) were re- 
moved from the above pool of samples after dehydration through 100% etha- 
nol, critical point dried, then sputter coated with gold. Tendon samples pre- 
pared for SEM were first dehydrated in a graded series of ethanol, critical 
point dried, sliced longitudinally with respect to the collagen fibers to allow 
direct antibody access to the tendon fibrils, then rehydrated directly in anti- 
body. Subsequent steps were as above. 
Rotary shadowed replicas of mAb-III-type III complexes were prepared 
as described previously (Morris et al.,  1986). 
TEM samples were observed using a Philips 410 L.S. electron micro- 
scope operated at 60 or 80 kV using a 30-~tm objective aperture. SEM sam- 
ples were observed using the upper stage of a LaB6 emitter equipped ISI 
DS  130 operated at 9 or 10 kV with the smallest available spot size. 
1. Abbreviations used in this paper: mAb-III, murine monoclonal anti-hu- 
man type III collagen IgM; SEM,  scanning electron microscopy; TEM, 
transmission electron microscopy. 
In vitro Preparation of  Collagen Fibrils 
Human type III collagen was prepared from amnion as previously described 
(Burgeson et al., 1976). Human type I collagen was solubilized from bone 
after decalcification of neonatal femurs by extraction with five changes of 
0.5 M EDTA, Tris-HCl pH 7.5, 1 wk each at 4~  Bones were homogenized 
using a polytron homogenizer (Brinkmann Instruments Co., Westbury,  N J) 
and digested with 0.5 mg/ml pepsin (Boehringer-Mannheim Diagnostics, 
Inc., Houston, TX) in 0.5 M acetic acid at 4~  for 48 h with constant agita- 
tion. Solubilized protein was clarified by centrifugation and precipitated by 
the addition of solid NaCI to 1.2 M. The harvested proteins were redissolved 
in 1 M NaCI, 50 mM Tris-HCl, pH 7.5, clarified by centrifugation and dia- 
lyzed versus 2.0 M NaCI, reclarified, and type I collagen was precipitated 
by dialysis versus 2.8 M NaCI. The precipitate was dissolved in 0.5 M acetic 
acid and reprecipitated by the addition of solid NaCI to 1.0 M. The precipi- 
tate was redissolved in 0.5 M acetic acid, extensively dialyzed versus 0.5 
M acetic acid, and lyophilized. The purity of the collagen preparations was 
tested by polyacrylamide gel electrophoresis and determined to be >95 % 
pure. The type III preparation contained 1-5% type I collgen; the type I 
preparation was free of type IlI collagen as determined by ELISA (not 
shown). 
Collagen types I and HI were dissolved in  10 mM HCI at 4~  to ",,2 
mg/ml. The exact concentration was determined by amino acid analysis, and 
adjusted to 0.8 mg/ml. Fibrils were formed for 24 h at 10~  as previously 
described (McPherson et al.,  1985). 
Miscellaneous Procedures 
Type III collagen renaturation, trypsin digestion, and characterization of 
tryptic fragments have been previously described (B/ichinger et al., 1980). 
Triple-helical fragments for ELISA were prepared by inactivating trypsin 
with TLCK at a final concentration of 1.0 mg/ml. ELISA was performed 
as previously described (Engvall  and Perlmann,  1972). 
Results 
Antibody Specificity 
IgM monoclonal anti-human type III collagen triple-helical 
domain (mAb-III) has been previously  reported  (Keene et 
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Figure 1.  ELISA reactivity of mAb-III with collagen types I-VII. 
The reactivity of mAb-III was titered versus collagen types I (x), 
II (o), III (e), IV (m), V  (*), VI (*), and VII (i) at dilutions from 
1:200  to  1:3.2  x  106. Reactivity with type III titered to ,,o1:5  x 
105. The apparent minor crossreactivities with types V  and VII re- 
sult from small amounts of type III collagen, which unavoidably 
contaminate these native preparations. 
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helical domain, mAb-III, type HI collagen antigen-antibody com- 
plexes, were visualized after rotary shadowing. The predominant 
site of binding is 90 nm from one end (A-E), but binding is occa- 
sionally seen at the end as well (F). Bar, 100 nm. 
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Figure 3. The epitope recognized by mAb-]]I is about one-third the 
distance from the amino terminus of the type lII triple helix. Heat- 
denatured  type III  collagen  was  renatured  at 25~  At  various 
renaturation times (x-axis), aliquots were tested for their ability (A) 
to demonstrate reactivity  to mAb-III or (B) to inhibit mAb-III bind- 
ing to native type I~ collagen by ELISA (y-axis). Peptides first ap- 
pearing at 10 min, and abundant at 15 and 20 min were analyzed 
by gel electrophoresis (not shown), which indicated these peptides 
included about two-thirds of the triple helix from the COOH- 
terminus (the COOH-terminus is the nucleation point of renatura- 
tion due to the presence of interchain disulfide bonds). Therefore, 
the recognized epitope lies approximately one-third the distance 
from the amino terminus, consistant with the data in Fig. 2, A-E. 
tested collagen, including types I, II, IV, V, VI, and VII as 
detected by ELISA (Fig. 1). mAb-lII titers to a 1:500,000 di- 
lution. At a  1:5,000 dilution, the antibody is completely in- 
hibited by 10 ng type III collagen (not shown). 
The Epitope Recognized by mAB-III 
Is about 300 Residues from the Amino Terminus 
of  the Triple Helix 
Antigen-antibody  complexes  were  analyzed  by  rotary 
shadowing. Antibody was most commonly localized to a re- 
gion ~90 nm from one end (Fig. 2). However, antibody was 
also occasionally seen binding to one end (Fig. 2 F). While 
end binding was relatively rare, further studies were under- 
taken to determine the site of the epitope.  As previously 
reported, exposure of partially renatured type III collagen to 
trypsin results in the generation of fragments with lengths 
reflecting the extent of triple-helix re-formation (B~ichinger 
et al.,  1980). Refolding starts at the carboxyl-terminal di- 
sulfide bonds and with increasing renaturation time larger 
and larger fragments appear upon tryptic digestion. Each of 
these timed digestions was tested for their ability (a) to react 
with mAb-III (Fig. 3 A), (b) to inhibit mAb-iiI binding to 
native type III collagen (Fig.  3  B),  and the sizes  of the 
trypsin-resistant peptides were evaluated by gel electropho- 
resis (not shown), mAb-III reactivity is detected by ELISA 
first with 10-min  fragments, and increases linearly until a 
maximum is established with 20-min fragments (Fig. 3 A). 
Likewise, inhibition was negligible with 10-min fragments 
and maximal with 20-min fragments (Fig. 3 B) coinciding 
with the appearance of electrophoretic bands g and h (B[ich- 
inger et al., 1980), which approximately correspond to pep- 
tides  including residues  350-1,018  and  250-1,018 respec- 
tively.  Therefore, these results indicated that the epitope is 
contained within 250-350 residues from the amino terminus 
or •75-105  nm from the amino terminus and confirmed the 
majority of the rotary shadowing evidence. 
Banded collagen fibrils were formed in vitro from pure 
type  I  collagen  obtained  from  human  bone  by  pepsin 
solubilization and from pure type III collagen isolated and 
purified from pepsin digests of human amnion as described 
(Materials and Methods). Molecules of IgM were directly 
visualized upon the surface of the type III collagen fibril by 
either TEM or SEM, but no binding to type I collagen fibrils 
was detected (Keene et al., 1987). Fibrils formed from mix- 
tures of types I and III collagens were similarly tested for 
maximal antibody binding by TEM. Fibrils formed from a 
mixure of  5 % type III and 95 % type I were labeled uniformly 
with antibody, indicating that as little as 5 % type III collagen 
in fibrils is easily detectable (Fig. 4). In a separate experi- 
ment (not shown), uniform labeling was also observed upon 
fibrils made from solutions containing 2.5% type III, non- 
uniform labeling was observed upon fibrils containing 1% 
type III collagen, and no detectable antibody bound fibrils 
of 0.2% or 0.1%. 
Keene et al.  Type 111 Collagen on Fibrils  2395 Figure 4. Transmission  electron microscopic immunolocalization  of type III collagen to fibrils formed in vitro from a solution containing 
95 % type I collagen, 5 % type III collagen. IgM antibodies can be uniformly seen along the surface of the fibril made from the 95 % 1/5 % 
III solution (A), but not along 100% type I fibrils (B). Both preparations were negatively  stained with 1% phosphotungstic  acid, pH 7.45. 
Bar, 100 nm. 
6 7-nm Periodically Banded Fibrils in 
Human Dermis Uniformly Label with mAb-III 
Regardless of  Fibril Diameter, Tissue Age, 
or Location within the Dermis 
Type HI collagen triple helix was immunolocalized within 
human dermis using mAb-III. As shown by SEM in Fig. 5, 
A and  C,  all fibrils in human neonatal foreskin observed 
within the field were uniformly  labeled with antibody. A cor- 
responding region incubated with human IgM did not cause 
visible IgM deposition (Keene et al., 1987), nor did antibod- 
ies of irrelevant specificity (Fig. 5, B and D). TEM localiza- 
tion of type III at the dermal epidermal junction of neonatal 
foreskin (Fig. 6 A), the reticular dermis of 14-yr-old toe skin 
(Fig. 6 B), the reticular dermis of ll-yr-old back skin (Fig. 
6 C), and the deep reticular dermis from 14-yr-old back skin, 
adjacent to the subcutaneous fat cells (Fig. 6 D), indicated 
that all fibrils were strongly labeled. As expected for a mono- 
clonal antibody that recognizes a  single epitope,  the ob- 
served antibody binding occurred at intervals •67  nm. The 
very fine microfibrils seen at the dermal-epidermal junction 
(Fig.  6  A)  more  closely  resembled  fibrillin microfibrils 
(Sakai et al.,  1986b)  and anchoring fibrils  (Sakai  et al., 
1986a) than uniformly banded collagen fibrils, but it is possi- 
ble that very fine banded fibrils may not label with mAb-III. 
Banded Fibrils in Human Tendon of  any Age, 
Amnion, and Aorta Label Uniformly with mAb..III 
Human Achilles tendon (ages 14 to 80 yr), term anmion, and 
aorta (age 14 yr) were also examined after exposure to mAb- 
III. The vast majority of collagen fibrils in tendon were seen 
to be uniformly labeled when examined by either TEM with- 
out (Fig. 7 A) or with collodial gold-conjugated second anti- 
body (Fig. 7 B), or SEM (Fig. 7, C and E). Tendon fibrils 
incubated by the  same  procedures  with antibodies  of ir- 
relevant specificity appeared relatively smooth, although a 
greater amount of debris is found along the control tendon 
surface (Fig.  7  D)  than was  seen with skin (Fig.  5).  As 
demonstrated for skin, this observation held for tendon re- 
gardless of donor age (tissue samples shown in Fig. 7 range 
from 77- to 80oyr-old;  results from 14-yr-old samples were 
identical [not shown]) and for fibrils with obvious differ- 
ences in diameters (Fig. 7 B).  Occasional fibrils (not ob- 
vious in these micrographs) were unlabeled. These tended 
to be small in diameter, and were unlabeled along their en- 
tire observable length. Adjacent fibrils were uniformly la- 
beled.  TEM examination of human amnion (Fig. 8 A) and 
aorta  (14-yr-old,  Fig.  8 B)  showed uniform deposition of 
mAb-III. 
Most Periodically Banded Fibrils in Human Cornea 
Are Unlabeled by mAb-lll 
Human cornea (age 15 yr) was similarly examined by TEM 
using mAb-III. As shown in Fig. 8, C and D, only occasional 
fibrils  were  labeled.  In  this  case,  to  be  certain  that  the 
deposits observed were IgM,  a  5-nm colloidal gold-con- 
jugated anti-mouse IgM antibody was  additionally used. 
The antibodies had adequate access to the tissue, as the la- 
beled  fibrils were  uniformly decorated along their entire 
exposed  length,  while  fibrils  immediately adjacent  were 
negative. 
Discussion 
The present studies indicate that 67-nm periodically banded 
fibrils in human skin, amnion, aorta, and Achilles tendon 
have type III collagen uniformly upon their surfaces. This 
observation contradicts previous studies that reported that 
only fibrils of  relatively small diameter were immunologically 
reactive to type III collagen specific antibodies. This discre- 
pancy may arise from the antibodies used in previous studies. 
The antisera used in previous studies (Nowack et al.,  1976; 
Fleischmajer et al., 1980) were made to neutral salt extracted 
type III collagen. Both antisera were absorbed against other 
collagen types, and both reacted with only a portion of the 
total collagen fibers in skin. It is most likely that these an- 
tisera reacted with portions of either the amino or carboxyl 
propeptides of type III collagen. Several  lines of evidence 
support this conclusion. First, since type III collagen is only 
slowly processed in vivo (Fessler et al., 1979) it is almost cer- 
tain that the immunogen contained type III molecules with 
at least partially intact propeptides. Absorption with other 
collagens would remove crossreacting anti-helical antibod- 
ies, but not those specific either to the type III helix or to the 
propeptides. In addition, ultrastructural immunolocalization 
The Journal of Cell Biology, Volume  105, 1987  2396 Figure 5.  Scanning electron microscopic immunolocalization of type III collagen within human dennis.  The dennis of neonatal human 
foreskin was examined by SEM after incubation with mAb-III OgM). Naked bound IgM is visualized along all fibrils and exhibits an ',,67- 
nm periodicity (,4 and C). Foreskin incubated with an antibody of irrelevant specificity demonstrates no binding (B and D). Bars: (A) 
250 nm; (B) 150 nm. 
using one of these antisera (and presumably the other would 
behave similarly since they were made according to identical 
procedures) showed binding at regular intervals of  65 nm, in- 
dicating recognition of highly clustered epitopes, and little 
or no reactivity of the remainder of the molecule. And also, 
the immunolocalization of type III collagen using this an- 
tisera was indistinguishable from that obtained with antibod- 
ies to type III procollagen (Nowack et al., 1976) or from that 
seen using  antibodies specific to the amino propeptide of 
type III procollagen (Fleischmajer et al.,  1981, 1983). 
Because of the above ambiguities,  the specificity of the 
monoclonal antibody used  in  the present study has  been 
Keene et al.  Type 111 Collagen  on Fibrils  2397 Figure 6. TEM immunolocalization of type HI collagen within human dermis.  Skin samples  from several sites of individuals  of varying 
ages were incubated  with mAb-III and visualized  by TEM. In all cases,  IgM is visualized  along each fibril regardless  of specimen age, 
site of biopsy,  location within  the biopsy,  or fibril diameter.  (A) Neonatal  foreskin,  dermal epidermal  junction; (B) plantar  surface toe 
skin, 14-yr-old, reticular dermis; (C) back skin,  U-yr-old,  reticular  dermis; (D) thigh skin, deep reticular  dermis near subcutaneous  fat 
layer,  14-yr-old. Bars: (A) 500 nm; (B)  150 nm. Figure 7. Electron microscopical immunolocalization  of type III collagen in human  tendon. Achilles tendon specimens from 77- to 80-yr-old 
individuals were incubated with mAb-IH and examined by TEM (A and B) and SEM (C and E). B was incubated with 5-nm colloidal 
gold-conjugated second antibody and shows periodic labeling of fibrils ranging in diameter from 32 to 130 nm. Almost all fibrils demon- 
strate IgM deposition. Unincubated control tendon (D) is not decorated  with IgM when examined.  Bars:  (,4) 500 nm; (D) 250 nm. The Journal of Cell Biology, Volume 105,  1987  2400 rigorously tested.  It  shows  no crossreactivity with  other 
tested collagens by ELISA. It reacts with in vitro formed 
fibrils only if they contain type III collagen, and the recog- 
nized epitope has been determined, mAb-III does not artifac- 
tually react with all periodically banded fibrils because it 
does not stain in vitro formed type I fibrils, nor does it stain 
all fibrils in human cornea. Because the epitope is within the 
type III collagen triple helix, positive tissue reactivity with 
mAb-III accurately indicates the presence of type III colla- 
gen  in  any  of its  known  forms  (i.e.,  procollagen,  pN- 
collagen, or pC-collagen). 
We were surprised to observe uniform labeling of tendon 
fibrils with anti-type III collagen antibody. Published chemi- 
cal studies of tendon collagens (Jimenez et al., 1978; Herr- 
mann et al.,  1980) indicate that type III contributes only a 
negligible proportion of the total collagen content. Chick 
tendon fibroblasts do not synthesize detectable amounts of 
type []  collagen in suspension culture, but do synthesize 
type III when grown in monolayer culture (Hermann et al., 
1980). Previous indirect immunotiuorescence studies (Becker 
et al., 1976; Herrmann et al., 1980) suggest that type HI col- 
lagen is restricted to the endotendineum of adult chick and 
human tendon, but its distribution may be somewhat broader 
in  13-d chick embryo. The former studies used antiserum 
that reacted only with non-helical epitopes; the reactivity of 
the antibodies used in the latter studies to helical versus non- 
helical epitopes was undetermined. Similarly, indirect im- 
munofluorescence  of  human tendon using the IgM antibodies 
described in this present report is not readily distinguishable 
from background unless the tissue is first processed by the 
procedures described here for immunoelectron microscopy 
(Keene, D. R., and L. Y. Sakai, unpublished observations). 
The failure to detect type III collagen within the fiber bundles 
of tendon without swelling in acid or exposing epitopes by 
slicing critical point dried specimens, could be explained by 
poor penetration of antibody. The small amount of type [] 
detected by chemical means is more difficult to understand, 
since the IgM antibody uniformly  labels only in vitro-formed 
fibrils made from solutions containing at least 1-2.5 % type 
III collagen. It is possible that this amount of type [] might 
be below the limits of detection by the chemical methods 
used. It is unlikely that the periodic binding oflgM to tendon 
fibrils is an artifact. IgM of irrelevant specificity shows no 
labeling of tendon; the IgM antibody does not label in vitro 
formed fibrils, which contain <1% type [] collagen. We have 
recently repeated the tendon ultrastructural immunolocal- 
ization experiments with another antibody, which we be- 
lieve is also specific for a helical epitope of type III collagen, 
but in this case the monoclonal antibody is an IgG. Identical 
results were obtained (Hori, H., and D. R. Keene, personal 
communication). From these studies, we conclude that type 
III collagen is present along at least the surface of tendon 
fibers, but it may represent only a small percentage of total 
tendon collagens. 
The finding that the collagen fibrils of human cornea are 
only occasionally labeled by the anti-type [] collagen anti- 
body contradicts the findings of Nakayasu et al. (1986) who 
report uniform distribution of type [] collagen throughout 
the human corneal stroma. Type [] has also been reported 
to be uniformly  present in bovine and rabbit cornea (Schmut, 
1977). There is no obvious explanation for the discrepancy. 
One possibility might be that the type III collagen epitope 
recognized by the IgM monoclonal antibody is blocked in 
human cornea, perhaps by proteoglycan, which localizes to 
specific sites along the corneal collagen fibrils (Scott and 
Haigh, 1985). The apparent lack of labeling is not likely to 
result from problems of incomplete antibody penetration be- 
cause when present, the antibody labels a single fibril along 
its entire observable length. Fibrils immediately adjacent are 
negative. We do not interpret the lack of antibody binding 
seen in these present experiments to demonstrate a sparcity 
of type [] collagen in human cornea. They do suggest that 
corneal fibrils are in some way different from those in other 
tissues studied. 
The observation that fibrils in skin, tendon, aorta, and am- 
nion contain type [] collagen upon their surfaces suggests 
that type [] is either restricted to the fibril surface, perhaps 
at the end stages of fibril growth, or that type [] is incorpo- 
rated throughout all growing fibrils in proportion to the per- 
cent type [] represents of total newly synthesized fibrillar 
collagen. The present study supports the latter conclusion, 
but the former cannot be excluded. The observation that type 
III collagen (or  procollagen)  is uniformly present on all 
fibrils in  rapidly growing skin (neonatal foreskin) where 
small fibrils are likely to represent growth intermediates, 
strongly suggests that type III procoUagen is involved in fibril 
growth regulation as previously suggested (Fleischmajer et 
al.,  1985) and as a consequence type [] collagen becomes 
incorporated throughout the resulting fibrils. 
The molecular events involved in the regulation of fibril 
length or girth remain unresolved, yet these studies do indi- 
cate that the triple-helical domains ofpN- or pC-type [] col- 
lagens seen on the surface of small diameter fibrils do be- 
come integral components of those fibrils. The presence of 
type III collagen or procollagen may accelerate or retard the 
fibril growth process, may modulate a structural/functional 
property of the fibrils themselves, or some combination of 
these possibilities. 
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